These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 29753732)
1. Niacin action in the atherogenic mixed dyslipidemia of metabolic syndrome: Insights from metabolic biomarker profiling and network analysis. Adiels M; Chapman MJ; Robillard P; Krempf M; Laville M; Borén J; J Clin Lipidol; 2018; 12(3):810-821.e1. PubMed ID: 29753732 [TBL] [Abstract][Full Text] [Related]
2. Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication of CETP. Chapman MJ; Orsoni A; Robillard P; Therond P; Giral P J Clin Lipidol; 2018; 12(3):784-800.e4. PubMed ID: 29574070 [TBL] [Abstract][Full Text] [Related]
3. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Nesto RW Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526 [TBL] [Abstract][Full Text] [Related]
4. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients. Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282 [TBL] [Abstract][Full Text] [Related]
5. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients. Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297 [TBL] [Abstract][Full Text] [Related]
6. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus. Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582 [TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390 [TBL] [Abstract][Full Text] [Related]
12. Cholesterol efflux and metabolic abnormalities associated with low high-density-lipoprotein-cholesterol and high triglycerides in statin-treated coronary men with low-density lipoprotein-cholesterol <70 mg/dl. Posadas-Sánchez R; Posadas-Romero C; Mendoza-Pérez E; Caracas-Portilla NA; Cardoso-Saldaña G; Medina-Urrutia A; Jorge-Galarza E; Juárez-Rojas JG Am J Cardiol; 2012 Mar; 109(5):636-41. PubMed ID: 22169129 [TBL] [Abstract][Full Text] [Related]
14. Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus. Ooi EM; Watts GF; Chan DC; Pang J; Tenneti VS; Hamilton SJ; McCormick SP; Marcovina SM; Barrett PH Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2686-93. PubMed ID: 26515419 [TBL] [Abstract][Full Text] [Related]
15. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial. Balasubramanyam A; Coraza I; Smith EO; Scott LW; Patel P; Iyer D; Taylor AA; Giordano TP; Sekhar RV; Clark P; Cuevas-Sanchez E; Kamble S; Ballantyne CM; Pownall HJ J Clin Endocrinol Metab; 2011 Jul; 96(7):2236-47. PubMed ID: 21565796 [TBL] [Abstract][Full Text] [Related]
16. Cardiometabolic risk factors in preschool children with abdominal obesity from Medellín, Colombia. Marín-Echeverri C; Aristizábal JC; Gallego-Lopera N; Santa-Ramírez HA; Hoyos-Gómez M; Ruiz-Pineda AM; Arias AA; Barona-Acevedo J J Pediatr Endocrinol Metab; 2018 Nov; 31(11):1179-1189. PubMed ID: 30367807 [TBL] [Abstract][Full Text] [Related]
17. Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation. Dubé MP; Komarow L; Fichtenbaum CJ; Cadden JJ; Overton ET; Hodis HN; Currier JS; Stein JH; Clin Infect Dis; 2015 Sep; 61(5):840-9. PubMed ID: 25979307 [TBL] [Abstract][Full Text] [Related]
18. The therapeutic role of niacin in dyslipidemia management. Boden WE; Sidhu MS; Toth PP J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):141-58. PubMed ID: 24363242 [TBL] [Abstract][Full Text] [Related]
19. Effect of colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose. Davidson MH; Rooney M; Pollock E; Drucker J; Choy Y J Clin Lipidol; 2013; 7(5):423-32. PubMed ID: 24079283 [TBL] [Abstract][Full Text] [Related]
20. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ; Watson KE; Talbert RL J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]